The global coronavirus pandemic has had a massive negative effect on personal finances. This has encouraged consumers to re-evaluate their pre-pandemic spending patterns, and make changes to their shopping lists to align with new budgets.
This report is part of the publisher's Consumer Behavior Tracking report series, which analyzes trends related to consumer sentiment, lifestyles, attitudes, and behaviors. The consumer insight offered throughout the report is drawn from the publisher's global consumer survey, a quarterly survey designed to capture consumer sentiment as it evolves throughout the year.
Scope
Explores how consumer spending patterns have changed in the past three months as a result of COVID-19.
Examines which product categories consumers are purchasing in the low, medium, or high price range.
Examines which product categories consumers are purchasing in low, medium, or high quantities.
Reasons to Buy
Gain a broader appreciation of the fast-moving consumer goods industry.
Understand the relevant consumer trends and attitudes that can drive and support innovation and brand strategy.
Access valuable strategic take-outs to help direct decision-making and inform new product development.
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor...
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...
The "Global Men's Health and Wellness Market: Analysis By Type, By Distribution Channel, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.
In 2023, the...